Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers
Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers
Clinical utility of circulating tumor‑associated cells to predict and monitor chemo‑response in solid tumors
Long Overall Survival in a Case of Refractory Stage IV Squamous Cell Carcinoma of Lung Treated with Personalized De Novo Combination Regimen
Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial
Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC
